- Home
- PMAX vs SNGX Comparison
PMAX vs SNGX Comparison
Compare PMAX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- SNGX
- Stock Information
- Founded
- PMAX 2019
- SNGX 1987
- Country
- PMAX Hong Kong
- SNGX United States
- Employees
- PMAX N/A
- SNGX N/A
- Industry
- PMAX
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- SNGX Health Care
- Exchange
- PMAX Nasdaq
- SNGX Nasdaq
- Market Cap
- PMAX 6.6M
- SNGX 6.1M
- IPO Year
- PMAX 2024
- SNGX 1987
- Fundamental
- Price
- PMAX $0.45
- SNGX $2.21
- Analyst Decision
- PMAX
- SNGX
- Analyst Count
- PMAX 0
- SNGX 0
- Target Price
- PMAX N/A
- SNGX N/A
- AVG Volume (30 Days)
- PMAX 820.9K
- SNGX 29.1K
- Earning Date
- PMAX 04-15-2025
- SNGX 05-09-2025
- Dividend Yield
- PMAX N/A
- SNGX N/A
- EPS Growth
- PMAX N/A
- SNGX N/A
- EPS
- PMAX 0.04
- SNGX N/A
- Revenue
- PMAX $5,970,263.00
- SNGX $119,371.00
- Revenue This Year
- PMAX N/A
- SNGX N/A
- Revenue Next Year
- PMAX N/A
- SNGX N/A
- P/E Ratio
- PMAX $8.96
- SNGX N/A
- Revenue Growth
- PMAX 30.05
- SNGX N/A
- 52 Week Low
- PMAX $0.28
- SNGX $1.83
- 52 Week High
- PMAX $4.70
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- SNGX 42.26
- Support Level
- PMAX N/A
- SNGX $2.25
- Resistance Level
- PMAX N/A
- SNGX $2.28
- Average True Range (ATR)
- PMAX 0.00
- SNGX 0.11
- MACD
- PMAX 0.00
- SNGX -0.01
- Stochastic Oscillator
- PMAX 0.00
- SNGX 35.48
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).